Clinical Trial

Antibacterial Effect of Zinc Oxide Nanoparticles on Acinetobacter Baumannii Isolated From Patients With Hospital Acquired Infections in Sohag University Hospitals, Egypt

Completed
View on ClinicalTrials.gov →
Summary
A. baumannii is known as the most frequently isolated organism in intensive care units (ICUs), causing a variety of nosocomial infections, including pneumonia, urinary tract infections (UTIs), bacteremia as well as skin and soft tissue infections. These infections are usually associated with high mortality rates ranging between 26% among hospitalized patients and 43% among ICU patients.
Protocol Amendment History 1 change
critical Completed without a posted recruiting period 2026-08-14
Trial Details
NCT Number NCT06628076
Lead Sponsor Sohag University
Conditions Infections, Nosocomial, Infections, Respiratory Tract
Enrollment 150 participants
Start Date 2024-10-10
Primary Completion 2024-10-10 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-13